LC
Laura Chico Wedbush Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Dianthus Therapeutics
DNTH
$853M
| $26.50 | $42 |
58%
upside
| Outperform | 15 days ago |
|
|
JBIO
2
Jade Biosciences, Inc. Common Stock
JBIO
$254M
| $7.77 | $18 |
132%
upside
| Outperform | 22 days ago |
|
3
Solid Biosciences
SLDB
$428M
| $5.50 | $14 |
155%
upside
| Outperform | 23 days ago |
|
4
Stoke Therapeutics
STOK
$1.13B
| $20.68 | $22 |
6%
upside
| Outperform | 23 days ago |
|
5
Xenon Pharmaceuticals
XENE
$3.02B
| $39.21 | $43 |
10%
upside
| Outperform | 24 days ago |
|
6
Travere Therapeutics
TVTX
$1.93B
| $21.64 | $32 |
48%
upside
| Outperform | 29 days ago |
|
7
Gossamer Bio
GOSS
$668M
| $2.94 | $5 |
70%
upside
| Outperform | 1 month ago |
|
8
Ardelyx
ARDX
$1.57B
| $6.52 | $14 |
115%
upside
| Outperform | 1 month ago |
|
9
Neurocrine Biosciences
NBIX
$14.3B
| $144.10 | $141 |
2%
downside
| Outperform | 1 month ago |
|
10
Ultragenyx Pharmaceutical
RARE
$3.07B
| $31.82 | $34 |
7%
upside
| Neutral | 1 month ago |
|
|
MAZE
11
Maze Therapeutics, Inc. Common Stock
MAZE
$696M
| $15.88 | $17 |
7%
upside
| Outperform | 1 month ago |
|
12
BioCryst Pharmaceuticals
BCRX
$1.74B
| $8.27 | $18 |
118%
upside
| Outperform | 2 months ago |
|
13
Larimar Therapeutics
LRMR
$337M
| $3.94 | $15 |
281%
upside
| Outperform | 2 months ago |
|
14
Lennar Class A
LEN
$36.7B
| $141.88 | $130 |
8%
downside
| Neutral | 2 months ago |
|
15
Biogen
BIIB
$20.6B
| $140.67 | $121 |
14%
downside
| Neutral | 2 months ago |
|
16
Pharvaris
PHVS
$1.48B
| $23.05 | $27 |
17%
upside
| Outperform | 3 months ago |
|
17
Vera Therapeutics
VERA
$1.54B
| $24.19 | $26 |
7%
upside
| Neutral | 4 months ago |
|
18
Denali Therapeutics
DNLI
$2.26B
| $15.43 | $30 |
94%
upside
| Outperform | 4 months ago |
|
19
Praxis Precision Medicines
PRAX
$986M
| $46.85 | $28 |
40%
downside
| Underperform | 4 months ago |
|
20
Edgewise Therapeutics
EWTX
$1.64B
| $15.57 | $43 |
176%
upside
| Outperform | 4 months ago |
|
21
Tourmaline Bio
TRML
$687M
| $26.74 | $43 |
61%
upside
| Outperform | 5 months ago |
|
22
Astria Therapeutics
ATXS
$424M
| $7.52 | $28 |
272%
upside
| Outperform | 5 months ago |
|
23
Apellis Pharmaceuticals
APLS
$3.55B
| $28.13 | $29 |
3%
upside
| Neutral | 6 months ago |
|
24
Viridian Therapeutics
VRDN
$1.53B
| $18.72 | $42 |
124%
upside
| Outperform | 1 year ago |
|
25
Design Therapeutics
DSGN
$367M
| $6.45 | $5 |
22%
downside
| Neutral | 1 year ago |
|